Evonik stock reports on November 3, 2026, falls pre-market
Published on 10/27/2026 at 08:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness and reporting calendar
- Evonik's Investor Relations calendar schedules its third-quarter 2026 report for November 3, 2026.
- A July 8, 2026 item described Evonik's pharmaceutical contract-development and manufacturing activities in the United States.
- Evonik stock trades pre-market at EUR 21.23 at 8:04 a.m. CET at Lang & Schwarz on October 27, 2026, 0.33 percent below the Xetra close of October 26, 2026.
Evonik's Investor Relations calendar lists November 3, 2026, for reporting on third-quarter business development. Evonik stock trades pre-market at EUR 21.23 at 8:04 a.m. CET at Lang & Schwarz on October 27, 2026, 0.33 percent below the Xetra close of October 26, 2026 (EUR 21.30).
Reporting date ahead
The company has scheduled its third-quarter 2026 reporting for November 3, 2026, according to the Evonik Investor Relations calendar.
Pre-market indication
The indication is EUR 0.07 below the October 26 Xetra close. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Evonik stock.
Business and market context
An Evonik Investor Relations item dated July 8, 2026 describes the group's contract-development and manufacturing work for pharmaceutical customers in the United States. Market context: Market report DAX.
